Core Viewpoint - The article discusses the controversy surrounding the product "麦角硫因胶囊" (Ergothioneine capsules) from 科伦药业 (Kelong Pharmaceutical), with prominent biologist 饶毅 (Rao Yi) labeling it as a "fake drug" due to lack of sufficient evidence for its efficacy [1][3]. Company Position - 科伦药业 asserts that 麦角硫因 is marketed as a "functional health product" rather than a drug, emphasizing that it has scientific backing and clinical research from overseas [1]. - The product is priced at 1499 yuan per bottle (60 capsules) and is promoted as having superior antioxidant effects compared to traditional ingredients like Vitamin C and Coenzyme Q10 [2]. Regulatory Status - 麦角硫因 has not received registration or approval from the National Market Supervision Administration, which classifies it as a regular food product, prohibiting any claims of health benefits [3]. Market Reaction - Following 饶毅's article, both 科伦药业 and 川宁生物 (Chuaning Biological) experienced stock price declines, with 科伦药业 dropping 4.96% to 37.75 yuan per share and 川宁生物 falling 1.98% to 12.87 yuan per share on June 5 [3]. - The downward trend continued on June 6, with 科伦药业 and 川宁生物's stock prices decreasing by 1.3% and 1.55%, respectively [3].